Amgenvs.Incyte
AMGN vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 8.5× larger than Incyte by market cap; Incyte trades at the lower P/E (16.1 vs 25.1); year to date, Incyte leads (+18.2% vs +11.0%).
Side by side
| AMGN | INCY | |
|---|---|---|
| Market cap | $196B | $23.1B |
| Price | $363.39 | $116.71 |
| Today | −0.1% | −1.5% |
| Return YTD | +11.0% | +18.2% |
| Return 1Y | +21.0% | +65.9% |
| P/E | 25.1 | 16.1 |
| P/S | 5.3 | 4.3 |
| P/B | 21.3 | 4.1 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AmgenAMGN
Veteran American biotech with a broad portfolio in oncology, immunology and bone diseases — and an obesity candidate (MariTide) in the pipeline.
Full AMGN profile →More comparisons in Biotech & innovation
See where AMGN and INCY sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →